NCT05077709 - IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

January 4, 2024

Study Completion Date

November 30, 2024

Conditions

Lung Cancer Non Small CellHead and Neck Squamous Cell CarcinomaUrothelial Carcinoma Bladder

Interventions

DRUG

IO102-IO103 in combination with pembrolizumab

The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides

Trial Locations (21)

10467

Montefiore Medical Center, The Bronx

17007

Hospital Universitari de Girona Doctor Josep Trueta, Girona

19104

University of Pennsylvania, Philadelphia

22031

Virginia Cancer Specialists, Fairfax

28034

Hospital Universitario Ramon y Cajal, Madrid

28040

Hospital Universitario Fundación Jiménez Díaz, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29010

Hospital Universitario Virgen de la Victoria, Málaga

32763

Mid Florida Hematology and Oncology Center, Orange City

41009

Hospital Universitario Virgen Macarena, Seville

43614

University of Toledo Medical Center, Toledo

50009

Hospital Clínico Lozano Blesa, Zaragoza

91010

City of Hope, Duarte

92093

University of California San Diego, San Diego

95817

UC Davis Cancer Center, Sacramento

97239

Oregon Health & Science University, Portland

08035

Hospital Vall d'Hebron, Barcelona

08916

Institut Català d'Oncologia (ICO) Badalona (Catalan Institute of Oncology), Barcelona

Unknown

Hospital Clínico Universitario de Valencia, Valencia

Guys and St Thomas Hospital, London

CF14 2TL

Velindre Cancer Center, Cardiff